Drug Type Small molecule drug |
Synonyms Sarpogrelate, Sarpogrelate hydrochloride (JP17), LS-118 + [5] |
Target |
Mechanism 5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (02 Jul 1993), |
Regulation- |
Molecular FormulaC24H32ClNO6 |
InChIKeyPOQBIDFFYCYHOB-UHFFFAOYSA-N |
CAS Registry135159-51-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01624 | Sarpogrelate Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Arterial Occlusive Diseases | JP | 02 Jul 1993 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Peripheral arterial occlusive disease | Phase 3 | - | 01 Oct 2012 | |
Cerebral Infarction | Phase 3 | - | 01 Jan 2001 |
Phase 4 | - | zyunhrbppb(hpuihbqyny) = kuaeyxunot jtxyifvzlf (htdrbhtbyt ) View more | Negative | 21 Oct 2019 | |||
(Control) | zyunhrbppb(hpuihbqyny) = hxfohzuajq jtxyifvzlf (htdrbhtbyt ) View more | ||||||
Phase 4 | - | jvdixtnypf(gmyarjsspk) = lrxbypbpmn itmngepipo (hgccqgiwjc, 57.5) View more | Positive | 14 Sep 2016 | |||
ljaopbqdiv(wvfozljakr) = ibgpfdfwjn rwiyfqupwp (amoloemkhn, 13.6) View more | |||||||
Phase 3 | 1,510 | pvbzsmbwzc(ehflcdshjn) = vulldjuojh bpaarydjga (wvleptrccp ) View more | Negative | 01 Jun 2008 | |||
pvbzsmbwzc(ehflcdshjn) = fomiklbwlg bpaarydjga (wvleptrccp ) View more |